A Phase 1 Multi-Center Trial of Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab
Phase of Trial: Phase I
Latest Information Update: 03 Jul 2019
Price : $35 *
At a glance
- Drugs Pertuzumab (Primary) ; Tocilizumab (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 06 May 2019 Planned End Date changed from 1 Aug 2019 to 1 Aug 2020.
- 06 May 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.
- 31 Aug 2018 Biomarkers information updated